Search Results
You are looking at 1 - 3 of 3 items for
- Author: Fabio Rotondo x
- Refine by access: All content x
Search for other papers by Luis V Syro in
Google Scholar
PubMed
Search for other papers by Fabio Rotondo in
Google Scholar
PubMed
Search for other papers by Leon D Ortiz in
Google Scholar
PubMed
Search for other papers by Kalman Kovacs in
Google Scholar
PubMed
Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance.
Search for other papers by Andrea Weckman in
Google Scholar
PubMed
Search for other papers by Fabio Rotondo in
Google Scholar
PubMed
Search for other papers by Antonio Di Ieva in
Google Scholar
PubMed
Search for other papers by Luis V Syro in
Google Scholar
PubMed
Search for other papers by Henriett Butz in
Google Scholar
PubMed
Search for other papers by Michael D Cusimano in
Google Scholar
PubMed
Search for other papers by Kalman Kovacs in
Google Scholar
PubMed
Autophagy is an important intracellular process involving the degradation of cytoplasmic components. It is involved in both physiological and pathological conditions, including cancer. The role of autophagy in cancer is described as a ‘double-edged sword,’ a term that reflects its known participation in tumor suppression, tumor survival and tumor cell proliferation. Available research regarding autophagy in endocrine cancer supports this concept. Autophagy shows promise as a novel therapeutic target in different types of endocrine cancer, inhibiting or increasing treatment efficacy in a context- and cell-type-dependent manner. At present, however, there is very little research concerning autophagy in endocrine tumors. No research was reported connecting autophagy to some of the tumors of the endocrine glands such as the pancreas and ovary. This review aims to elucidate the roles of autophagy in different types of endocrine cancer and highlight the need for increased research in the field.
Search for other papers by Michael Solarski in
Google Scholar
PubMed
Search for other papers by Fabio Rotondo in
Google Scholar
PubMed
Lady Davis Institute, Jewish General Hospital and Research Institute, McGill University Health Centre, Montreal, Quebec, Canada
Search for other papers by William D Foulkes in
Google Scholar
PubMed
Search for other papers by John R Priest in
Google Scholar
PubMed
Search for other papers by Luis V Syro in
Google Scholar
PubMed
Search for other papers by Henriett Butz in
Google Scholar
PubMed
Search for other papers by Michael D Cusimano in
Google Scholar
PubMed
Search for other papers by Kalman Kovacs in
Google Scholar
PubMed
In this review, the importance of the DICER1 gene in the function of endocrine cells is discussed. There is conclusive evidence that DICER1 mutations play a crucial role in the development, progression, cell proliferation, therapeutic responsiveness and behavior of several endocrine tumors. We review the literature of DICER1 gene mutations in thyroid, parathyroid, pituitary, pineal gland, endocrine pancreas, paragangliomas, medullary, adrenocortical, ovarian and testicular tumors. Although significant progress has been made during the last few years, much more work is needed to fully understand the significance of DICER1 mutations.
